CD8A and cancer: Abrogation of cancer-cell responsiveness to IFNγ (Extended Data Fig. 8a) was sufficient to negate the therapeutic activity of DCP-IL-12/FLT3L in mice (Fig. 4m), despite the observed enhancement of intratumoral CD8+ T cell infiltration and activation (Fig. 4n,o).